LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

NCT04219319 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Both the sponsors and collaborator are considering terminating the study

Conditions

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

Interventions

DRUG: Efficacy of LCAR-T2C CAR-T cells

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]